ecteinascidin 743 has been researched along with Meningeal Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balaná, C; Bendszus, M; Bonneville-Levard, A; Brandal, P; Brazil, L; Bromberg, J; Bronnimann, C; Bruna, J; Cameron, A; Clement, PM; Coens, C; Ducray, F; Dumont, S; Erridge, S; Furtner, J; Golfinopoulos, V; Gorlia, T; Le Rhun, E; Lefranc, F; Lewis, J; Lombardi, G; Lorgis, V; Mair, MJ; Marosi, C; Mawrin, C; Pichler, J; Preusser, M; Reijneveld, JC; Sahm, F; Sanson, M; Sepulveda, JM; Sievers, P; Silvani, A; Soffietti, R; Thon, N; Vauleon, E; Weller, M; Wick, W | 1 |
| Alvarez-Breckenridge, CA; Brastianos, PK; Cahill, DP | 1 |
| Badalamenti, G; Bello, E; Casali, PG; Collini, P; Colombo, C; Cominetti, D; D'Incalci, M; Dagrada, GP; Dei Tos, AP; Frapolli, R; Gronchi, A; Morosi, C; Negri, T; Pilotti, S; Provenzano, S; Renne, SL; Saponara, M; Stacchiotti, S; Tortoreto, M; Vincenzi, B; Zaffaroni, N; Zuco, V | 1 |
| Alfaro, J; Alvarez, M; Cebollero, A; Felipo, F; Madani, J; Martinez-Trufero, J | 1 |
| Berger, W; Dieckmann, K; Lötsch, D; Marosi, C; Preusser, M; Saringer, W; Schmook, M; Spiegl-Kreinecker, S; Wöhrer, A | 1 |
1 trial(s) available for ecteinascidin 743 and Meningeal Neoplasms
| Article | Year |
|---|---|
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).
Topics: Adult; Brain Neoplasms; Disease-Free Survival; Humans; Meningeal Neoplasms; Meningioma; Quality of Life; Trabectedin; World Health Organization | 2022 |
4 other study(ies) available for ecteinascidin 743 and Meningeal Neoplasms
| Article | Year |
|---|---|
Trabectedin for recurrent WHO grade 2 or 3 meningiomas-Paving the road for new opportunities.
Topics: Brain Neoplasms; Humans; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Local; Trabectedin; World Health Organization | 2022 |
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cerebellar Neoplasms; Dacarbazine; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Furans; Humans; Ifosfamide; Ketones; Kidney Neoplasms; Male; Meningeal Neoplasms; Mice, SCID; Middle Aged; Pleural Neoplasms; Response Evaluation Criteria in Solid Tumors; Retroperitoneal Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Solitary Fibrous Tumors; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays | 2017 |
Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Hemangiopericytoma; Humans; Male; Meningeal Neoplasms; Neoplasm Staging; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2010 |
Trabectedin has promising antineoplastic activity in high-grade meningioma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dioxoles; Drug Evaluation, Preclinical; Humans; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured | 2012 |